Volume 12 Issue 3
May  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2021  >  12(3): 272-279
Liu Shaoru, Xu Leibo. Immunotherapy of recurrence and metastasis after liver transplantation for liver cancer[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 272-279. doi: 10.3969/j.issn.1674-7445.2021.03.004
Citation: Liu Shaoru, Xu Leibo. Immunotherapy of recurrence and metastasis after liver transplantation for liver cancer[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 272-279. doi: 10.3969/j.issn.1674-7445.2021.03.004
shu

Immunotherapy of recurrence and metastasis after liver transplantation for liver cancer

doi: 10.3969/j.issn.1674-7445.2021.03.004

  • Department of Biliary and Pancreatic Surgery, Organ Transplantation Center, the Memorial Hospital of Sun Yat-sen University, Guangzhou 510288, China

More Information
  • Corresponding author: Xu Leibo, Email: xuleibo3@mail.sysu.edu.cn
  • Received Date: 2021-01-22
    Available Online: 2021-05-19
  • Publish Date: 2021-05-15
    Abstract
  • Primary liver cancer (liver cancer) is one of the main indications of liver transplantation in China. Nevertheless, the 5-year survival rate of liver transplant recipients is lower than 50%. Recurrence and metastasis after operation are the main causes affecting the long-term survival of the recipients. At present, immunotherapy, represented by programmed cell death protein 1(PD-1)/programmed cell death protein-ligand 1(PD-L1) immune checkpoint inhibitor, has achieved remarkable clinical efficacy in the treatment of middle-stage and advanced liver cancer. However, whether it can be applied in recipients with recurrence and metastasis after liver transplantation for liver cancer remains controversial. The main reason is that it may cause acute rejection at the same time. In this article, the research progresses on the application of immunotherapy in recipients with recurrence and metastasis after liver transplantation for liver cancer were reviewed, aiming to improve the survival rate of recipients undergoing liver transplantation forliver cancer.

     

    • FullText(HTML)
  • loading
    • References(46)
  • [1]
    SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI: 10.3322/caac.21551.
    [2]
    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    Medical Administration and Hospital Administration of the National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition) [J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [3]
    EGGERMONT AMM, BLANK CU, MANDALA M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma[J]. N Engl J Med, 2018, 378(19): 1789-1801. DOI: 10.1056/NEJMoa1802357.
    [4]
    HELLMANN MD, CIULEANU TE, PLUZANSKI A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22): 2093-2104. DOI: 10.1056/NEJMoa1801946.
    [5]
    QIN S, REN Z, MENG Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580. DOI: 10.1016/S1470-2045(20)30011-5.
    [6]
    中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.

    Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Branch of Organ Transplantation of Chinese Medical Association. The clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2018 edition) [J]. J Clin Hepatol, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.
    [7]
    MA LJ, FENG FL, DONG LQ, et al. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma[J]. Theranostics, 2018, 8(20): 5690-5702. DOI: 10.7150/thno.28742.
    [8]
    CALDERARO J, ROUSSEAU B, AMADDEO G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features[J]. Hepatology, 2016, 64(6): 2038-2046. DOI: 10.1002/hep.28710.
    [9]
    DAI X, XUE J, HU J, et al. Positive expression of programmed death ligand 1 in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma[J]. Transl Oncol, 2017, 10(4): 511-517. DOI: 10.1016/j.tranon.2017.03.009.
    [10]
    MORITA M, FUJINO M, JIANG G, et al. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft[J]. Am J Transplant, 2010, 10(1): 40-46. DOI: 10.1111/j.1600-6143.2009.02859.x.
    [11]
    DANG N, WAER M, SPRANGERS B, et al. Intratumoral immunotherapy with anti-PD-1 and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts[J]. Am J Transplant, 2021, 21(1): 60-72. DOI: 10.1111/ajt.16105.
    [12]
    LIPSON EJ, NAQVI FF, LOSS MJ, et al. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection[J]. Am J Transplant, 2020, 20(8): 2264-2268. DOI: 10.1111/ajt.15856.
    [13]
    王英, 余希, 施明, 等. 肝移植术后急性排斥患者外周血中T淋巴细胞上PD-1分子表达的特征及意义[J]. 细胞与分子免疫学杂志, 2013, 29(12): 1312-1314. https://www.cnki.com.cn/Article/CJFDTOTAL-XBFM201312023.htm

    WANG Y, YU X, SHI M, et al. Characteristics and significance of PD-1 on T lymphocytes in peripheral blood of acute rejection patients after liver transplantation[J]. Chin J Cell Mol Immunol, 2013, 29(12): 1312-1314. https://www.cnki.com.cn/Article/CJFDTOTAL-XBFM201312023.htm
    [14]
    ZENG Q, YUAN XY, LI W, et al. Effects of tacrolimus (FK506) and mycophenolate mofetil (MMF) on regulatory T cells and co-inhibitory receptors in the peripheral blood of human liver allograft patients[J]. Immunopharmacol Immunotoxicol, 2019, 41(3): 380-385. DOI: 10.1080/08923973.2018.1533026.
    [15]
    ZENG Q, YUAN X, CAO J, et al. Mycophenolate mofetil enhances the effects of tacrolimus on the inhibitory function of regulatory T cells in patients after liver transplantation via PD-1 and TIGIT receptors[J]. Immunopharmacol Immunotoxicol, 2021, 43(2): 239-246. DOI: 10.1080/08923973.2021.1891247.
    [16]
    SU Z, DHUSIA K, WU Y. A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells[J]. PLoS Comput Biol, 2021, 17(3): e1008825. DOI: 10.1371/journal.pcbi.1008825.
    [17]
    NING Z, LIU K, XIONG H. Roles of BTLA in immunity and immune disorders[J]. Front Immunol, 2021, 12: 654960. DOI: 10.3389/fimmu.2021.654960.
    [18]
    CHEN W, PANDEY M, SUN H, et al. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1[J]. MAbs, 2021, 13(1): 1914359. DOI: 10.1080/19420862.2021.1914359.
    [19]
    CHEN X, GAO A, ZHANG F, et al. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation[J]. Theranostics, 2021, 11(7): 3392-3416. DOI: 10.7150/thno.52435.
    [20]
    WANG M, MA X, ZHOU K, et al. Discovery of pyrrole-imidazole polyamides as PD-L1 expression inhibitors and their anticancer activity via immune and nonimmune pathways[J]. J Med Chem, 2021, DOI: 10.1021/acs.jmedchem.1c00120[Epub ahead of print].
    [21]
    SHAN T, CHEN S, CHEN X, et al. M2-TAM subsets altered by lactic acid promote T-cell apoptosis through the PD-L1/PD-1 pathway[J]. Oncol Rep, 2020, 44(5): 1885-1894. DOI: 10.3892/or.2020.7767.
    [22]
    汪国营, 唐晖, 张英才, 等. 程序性死亡受体(PD)-1单克隆抗体治疗肝癌肝移植术后复发诱发急性免疫性肝炎: 附1例报告[J]. 器官移植, 2016, 7(1): 44-47. DOI: 10.3969/j.issn.1674-7445.2016.01.008.

    WANG GY, TANG H, ZHANG YC, et al. Programmed death receptor (PD)-1 monoclonal antibody-induced acute immune hepatitis in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report[J]. Organ Transplant, 2016, 7(1): 44-47. DOI: 10.3969/j.issn.1674-7445.2016.01.008.
    [23]
    VARKARIS A, LEWIS DW, NUGENT FW. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma[J]. Am J Gastroenterol, 2017, 112(12): 1895-1896. DOI: 10.1038/ajg.2017.387.
    [24]
    GASSMANN D, WEILER S, MERTENS JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research[J]. Transplant Direct, 2018, 4(8): e376. DOI: 10.1097/TXD.0000000000000814.
    [25]
    FRIEND BD, VENICK RS, MCDIARMID SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma[J]. Pediatr Blood Cancer, 2017, 64(12). DOI: 10.1002/pbc.26682.
    [26]
    AMJAD W, KOTIAH S, GUPTA A, et al. Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with nivolumab[J]. J Clin Exp Hepatol, 2020, 10(2): 185-187. DOI: 10.1016/j.jceh.2019.11.009.
    [27]
    RAMMOHAN A, REDDY MS, FAROUK M, et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet? [J]. Hepatology, 2018, 67(3): 1166-1168. DOI: 10.1002/hep.29575.
    [28]
    DE TONI EN, GERBES AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient[J]. Gastroenterology, 2017, 152(6): 1631-1633. DOI: 10.1053/j.gastro.2017.01.063.
    [29]
    DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6): 1054-1062. DOI: 10.21037/jgo.2018.07.05.
    [30]
    KUO JC, LILLY LB, HOGG D. Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review[J]. Melanoma Res, 2018, 28(1): 61-64. DOI: 10.1097/CMR.0000000000000410.
    [31]
    MORALES RE, SHOUSHTARI AN, WALSH MM, et al. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation[J]. J Immunother Cancer, 2015, 3: 22. DOI: 10.1186/s40425-015-0066-0.
    [32]
    RANGANATH HA, PANELLA TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma[J]. J Immunother, 2015, 38(5): 211. DOI: 10.1097/CJI.0000000000000077.
    [33]
    SCHVARTSMAN G, PEREZ K, SOOD G, et al. Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma[J]. Ann Intern Med, 2017, 167(5): 361-362. DOI: 10.7326/L17-0187.
    [34]
    DE BRUYN P, VAN GESTEL D, OST P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?[J]. Curr Opin Oncol, 2019, 31(2): 54-64. DOI: 10.1097/CCO.0000000000000505.
    [35]
    CHEN DS, MELLMAN I. Elements of cancer immunity and the cancer-immune set point[J]. Nature, 2017, 541(7637): 321-330. DOI: 10.1038/nature21349.
    [36]
    AGUIRRE LE, GUZMAN ME, LOPES G, et al. Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue[J]. Oncologist, 2019, 24(3): 394-401. DOI: 10.1634/theoncologist.2018-0195.
    [37]
    TIO M, RAI R, EZEOKE OM, et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection[J]. Eur J Cancer, 2018, 104: 137-144. DOI: 10.1016/j.ejca.2018.09.017.
    [38]
    EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
    [39]
    GARANT A, GUILBAULT C, EKMEKJIAN T, et al. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review[J]. Crit Rev Oncol Hematol, 2017, 120: 86-92. DOI: 10.1016/j.critrevonc.2017.10.009.
    [40]
    BARNETT R, BARTA VS, JHAVERI KD. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab[J]. N Engl J Med, 2017, 376(2): 191-192. DOI: 10.1056/NEJMc1614298.
    [41]
    YE Q, LING S, JIANG G, et al. Sirolimus-based immunosuppression improves the prognosis of liver transplantation recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan criteria[J]. Eur J Surg Oncol, 2021, DOI: 10.1016/j.ejso.2021.04.001[Epub ahead of print].
    [42]
    BONNEFOY N, OLIVE D, VANHOVE B. Next generation of anti-immune checkpoints antibodies[J]. Med Sci (Paris), 2019, 35(12): 966-974. DOI: 10.1051/medsci/2019193.
    [43]
    PRICEMAN SJ, TILAKAWARDANE D, JEANG B, et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain[J]. Clin Cancer Res, 2018, 24(1): 95-105. DOI: 10.1158/1078-0432.CCR-17-2041.
    [44]
    KOCHENDERFER JN, SOMERVILLE RPT, LU T, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels[J]. J Clin Oncol, 2017, 35(16): 1803-1813. DOI: 10.1200/JCO.2016.71.3024.
    [45]
    MAUDE SL, LAETSCH TW, BUECHNER J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 439-448. DOI: 10.1056/NEJMoa1709866.
    [46]
    WEBER EW, MAUS MV, MACKALL CL. The emerging landscape of immune cell therapies[J]. Cell, 2020, 181(1): 46-62. DOI: 10.1016/j.cell.2020.03.001.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1198) PDF downloads(104) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return